Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Maria Rosario Chica-Parrado"'
Autor:
Julio Montes-Torres, Cynthia Robles-Podadera, Isabel Barragán-Mallofret, José M. Jerez, Martina Alvarez, Ana Godoy, Luis Vicioso, Begoña Jimenez, L. Perez-Villa, Nuria Ribelles, Maria Rosario Chica-Parrado, Emilio Alba
Publikováno v:
Cancer Research. 80:P1-10
Introduction: While pCR has been amply associated with improved treatment outcome in patients treated with NAC and surgery, there are only few studies that explore the molecular determinants of pCR. Given the discrete percentage of patients who achie
Autor:
Maria Rosario Chica Parrado, Maria Auxiliadora Gómez-España, Eduardo Díaz-Rubio, Manuel Benavides, Ana Vivancos, Marta Toledano, Enrique Aranda, Vanesa García-Barberán, Martina Alvarez, Elena Elez
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-8 (2019)
Scientia
Recercat. Dipósit de la Recerca de Catalunya
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Scientific Reports
Scientia
Recercat. Dipósit de la Recerca de Catalunya
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Scientific Reports
KRAS mutations are common in colorectal cancer (CRC). In this setting, mutation status determination in circulating-free DNA from blood samples (liquid biopsy) has been shown to be a viable alternative to tissue testing. The objective of this study w
Autor:
Begoña Jimenez, Maria Rosario Chica-Parrado, Emilio Alba, Isabel Barragan, Nuria Ribelles, Ana Godoy-Ortiz
Publikováno v:
Cancers
Cancers, Vol 12, Iss 2012, p 2012 (2020)
Cancers, Vol 12, Iss 2012, p 2012 (2020)
Neoadjuvant Chemotherapy (NAC) in Breast Cancer (BC) has proved useful for the reduction in tumor burden prior to surgery, allowing for a more extensive breast preservation and the eradication of subjacent micrometastases. However, the impact on prog
Autor:
Ana Godoy-Ortiz, Alfonso Sanchez-Muñoz, Maria Rosario Chica Parrado, Martina Álvarez, Nuria Ribelles, Antonio Rueda Dominguez, Emilio Alba
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Frontiers in Oncology
Frontiers in Oncology
The main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer progression, creating a sig
Autor:
Manuel Cobo, Elena Gallego, Isabel Barragan, Maria Rosario Chica-Parrado, Alicia Garrido-Aranda, Iñaki Comino, Alfonso Pérez Sánchez, Javier Oliver, Maria Jose Lozano, Aurora Laborda-Illanes, Juan Luis Onieva, Pedro Jimenez, Daniel Prieto, Cynthia Robles-Podadera, Miguel Angel Berciano-Guerrero, Martina Alvarez, Vanessa de Luque, Emilio Alba
Publikováno v:
Cancer Research. 80:281-281
Melanoma comprises a variety of malignant cell types from the skin, the mucous membranes, and the pigmented cells of the eye. Its incidence and mortality rates continue to rise worldwide, mainly driven by increased ultraviolet light exposure. Althoug
Autor:
María Rosario Chica-Parrado, Ana Godoy-Ortiz, Begoña Jiménez, Nuria Ribelles, Isabel Barragan, Emilio Alba
Publikováno v:
Cancers, Vol 12, Iss 8, p 2012 (2020)
Neoadjuvant Chemotherapy (NAC) in Breast Cancer (BC) has proved useful for the reduction in tumor burden prior to surgery, allowing for a more extensive breast preservation and the eradication of subjacent micrometastases. However, the impact on prog
Externí odkaz:
https://doaj.org/article/6871ed6d9ef84e849507020fa7a68291